Last edition
News about "Cosentyx "
US FDA Approves Novartis' Cosentyx for Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
The FDA has approved Novartis’ Cosentyx for patients aged 12 years and above with moderate-to-severe Hidradenitis Suppurativa (HS), marking the therapy’s fourth paediatric indication and expanding treatment options with a differentiated IL-17A mechanism.
Cosentyx | 16/03/2026 | By News Bureau
Novartis Signs Brain Delivery Deal With Sironax, Wraps pCPA Talks on Cosentyx Reimbursement
Novartis has signed an exclusive option agreement with Chinese biotech firm Sironax to potentially acquire its proprietary Brain Delivery Module (BDM) platform and concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx.
Cosentyx | 11/07/2025 | By Dineshwori | 300
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy